Dabigatran attenuates thrombin generation to a lesser extent than warfarin: Could this explain their differential effects on intracranial hemorrhage and myocardial infarction?

Journal of Thrombosis and Thrombolysis

Volumn 35, Issue 2, 2013, Pages 295-301

  Dale, Brian ^a   Eikelboom, John W ^b,c,d,e   Weitz, Jeffrey I ^b,c   Young, Ed ^c   Paikin, Jeremy S ^b   Coppens, Michiel ^d   Whitlock, Richard P ^b   Connolly, Stuart J ^b   Ginsberg, Jeffrey S ^b   Hirsh, Jack ^b,d  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^b MCMASTER UNIVERSITY   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d MCMASTER UNIVERSITY   (Canada)

^e 237 Barton Street East ^*  (Canada)

Author keywords

Dabigatran; Thrombin generation; Warfarin

Indexed keywords

DABIGATRAN; THROMBIN; WARFARIN;

ARTICLE; BLOOD SAMPLING; BRAIN HEMORRHAGE; CLINICAL ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; ENZYME BLOOD LEVEL; ENZYME INHIBITION; HEART INFARCTION; HUMAN; INTERNATIONAL NORMALIZED RATIO; PRIORITY JOURNAL;

ANTICOAGULANTS; ANTITHROMBINS; BENZIMIDAZOLES; BETA-ALANINE; FEMALE; HUMANS; INTRACRANIAL HEMORRHAGES; MALE; MYOCARDIAL INFARCTION; THROMBIN; WARFARIN;

EID: 84876010146     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-012-0857-9     Document Type: Article

References (17)

1. Ezekowitz MD, Connolly S, Parekh A, Reilly PA, Varrone J, Wang S et al (2009) Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. Am Heart J 157(805-10):810
2. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139-1151
3. Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin L (2010) Newly identified events in the RE-LY trial. N Engl J Med 363:1875-1876
4. Hart RG, Diener HC, Yang S, Connolly SJ, Wallentin L, Reilly PA et al (2012) Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial. Stroke 43(6):1511-1517
5. Hohnloser SH, Oldgren J, Yang S, Wallentin L, Ezekowitz M, Reilly P et al (2012) Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY trial. Circulation 125(5):669-676
6. Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J et al (2011) Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 123:2363-2372
7. Gerotziafas GT, Depasse F, Busson J, Leflem L, Elalamy I, Samama MM (2005) Towards a standardization of thrombin generation assessment: the influence of tissue factor, platelets and phospholipids concentration on the normal values of Thrombogram-Thrombinoscope assay. Thromb J 3:16
8. Barenholz Y, Gibbes D, Litman BJ, Goll J, Thompson TE, Carlson RD (1977) A simple method for the preparation of homogeneous phospholipid vesicles. Biochemistry 16:2806-2810
9. Bloom JW, Nesheim ME, Mann KG (1979) Phospholipid-binding properties of bovine factor V and factor Va. Biochemistry 18:4419-4425
10. Chantarangkul V, Clerici M, Bressi C, Giesen PL, Tripodi A (2003) Thrombin generation assessed as endogenous thrombin potential in patients with hyper- or hypo-coagulability. Haematologica 88:547-554
11. van Veen JJ, Gatt A, Cooper PC, Kitchen S, Bowyer AE, Makris M (2008) Corn trypsin inhibitor in fluorogenic thrombin-generation measurements is only necessary at low tissue factor concentrations and influences the relationship between factor VIII coagulant activity and thrombogram parameters. Blood Coagul Fibrinolysis 19:183-189
12. Luddington R, Baglin T (2004) Clinical measurement of thrombin generation by calibrated automated thrombography requires contact factor inhibition. J Thromb Haemost 2:1954-1959
13. Lau A, Berry LR, Mitchell LG, Chan AK (2007) Effect of substrate and fibrin polymerization inhibitor on determination of plasma thrombin generation in vitro. Thromb Res 119:667-677
14. Macfarlane RG, Biggs R (1953) A thrombin generation test; the application in haemophilia and thrombocytopenia. J Clin Pathol 6:3-8
15. Hemker HC, Willems GM, Beguin S (1986) A computer assisted method to obtain the prothrombin activation velocity in whole plasma independent of thrombin decay processes. Thromb Haemost 56:9-17
16. van Veen JJ, Gatt A, Makris M (2008) Thrombin generation testing in routine clinical practice: are we there yet? Br J Haematol 142:889-903
17. He S, Wallen H, Bark N, Blomback M (2012) In vitro studies using a global hemostasis assay to examine the anticoagulation effects in plasma by the direct thrombin inhibitors: dabigatran and argatroban. J Thromb Thrombolysis [Epub Ahead of Print]